Immunogen (IMGN) Tops Q2 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- Wall St rises as AI momentum holds heading into key earnings, Fed decision
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
Tweet
Share
E-mailGet Alerts IMGN Hot Sheet
Join SI Premium – FREE
Immunogen (NASDAQ: IMGN) reported Q2 EPS of ($0.15), $0.03 better than the analyst estimate of ($0.18). Revenue for the quarter came in at $16.94 million versus the consensus estimate of $18.92 million.
GUIDANCE:
Immunogen sees FY2021 revenue of $65-75 million, versus the consensus of $69.33 million.
For earnings history and earnings-related data on Immunogen (IMGN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- CTS Corp. (CTS) Tops Q3 EPS by 10c ; Offers Guidance
- PayPal (PYPL) Tops Q3 EPS by 14c; lifts EPS guidance
- Sherwin-Williams (SHW) Misses Q3 EPS by 6c; offers guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
